Metabolomic and Inflammatory Effects of Oral Aspirin (ASA) in Subjects at Risk for Melanoma
Pilot Studies Assessing the Metabolomic and Inflammatory Effects of Oral Aspirin (ASA) in Human Subjects at Risk for Melanoma
Sponsor: University of Utah
Listed as NCT04062032, this PHASE2 trial focuses on Melanoma (Skin) and remains completed. Sponsored by University of Utah, it has been updated 7 times since 2016, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Mar 2022 — Jul 2024 [monthly]
Completed PHASE2
Status: Recruiting → Completed
-
Apr 2021 — Mar 2022 [monthly]
Recruiting PHASE2
-
Jan 2021 — Apr 2021 [monthly]
Recruiting PHASE2
▶ Show 2 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Sep 2019 — Nov 2020 [monthly]
Recruiting PHASE2
First recorded
Sep 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University of Utah
For direct contact, visit the study record on ClinicalTrials.gov .